Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
P/E ratio for Zynerba Pharmaceuticals, Inc. (ZYNE)
P/E ratio as of 2022: -0.65
According to Zynerba Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.65. At the end of 2021 the company had a P/E ratio of -3.01.
P/E ratio history for Zynerba Pharmaceuticals, Inc. from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2022 | -0.65 |
| 2021 | -3.01 |
| 2020 | -1.77 |
| 2019 | -4.23 |
| 2018 | -1.14 |
| 2017 | -5.05 |
| 2016 | -6.05 |
| 2015 | -3.58 |
| 2014 | -16.43 |
| 2013 | -146.32 |